Histone Deacetylase Inhibitors

"Histone Deacetylase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains.

Descriptor ID	D056572
MeSH Number(s)	D27.505.519.389.360
Concept/Terms	Histone Deacetylase Inhibitors Histone Deacetylase Inhibitors Deacetylase Inhibitors, Histone Inhibitors, Histone Deacetylase Histone Deacetylase Inhibitor Deacetylase Inhibitor, Histone Inhibitor, Histone Deacetylase HDAC Inhibitors Inhibitors, HDAC

Below are MeSH descriptors whose meaning is more general than "Histone Deacetylase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Histone Deacetylase Inhibitors [D27.505.519.389.360]

Below are MeSH descriptors whose meaning is related to "Histone Deacetylase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Histone Deacetylase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Histone Deacetylase Inhibitors" by people in this website by year, and whether "Histone Deacetylase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 48 publications over 24 distinct years, with a maximum of 5 publications in 2005

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1999	1	0	1
2001	0	1	1
2002	1	1	2
2003	0	1	1
2004	2	0	2
2005	4	1	5
2006	1	0	1
2007	0	2	2
2008	3	1	4
2009	2	0	2
2010	0	2	2
2011	1	0	1
2012	1	1	2
2013	3	1	4
2014	1	1	2
2015	3	1	4
2016	3	1	4
2017	0	2	2
2018	1	0	1
2019	1	0	1
2021	0	1	1
2022	0	1	1
2023	0	1	1
2024	1	0	1

Below are the most recent publications written about "Histone Deacetylase Inhibitors" by people in Profiles.

Ryu Tiger YK, Jain S, Barta SK, Tolu S, Estrella B, Sawas A, Lue JK, Francescone MM, Pro B, Amengual JE. Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma. Leuk Lymphoma. 2024 06; 65(6):736-745.

View in: PubMed
Lumpkin CJ, Harris AW, Connell AJ, Kirk RW, Whiting JA, Saieva L, Pellizzoni L, Burghes AHM, Butchbach MER. Evaluation of the orally bioavailable 4-phenylbutyrate-tethered trichostatin A analogue AR42 in models of spinal muscular atrophy. Sci Rep. 2023 06 26; 13(1):10374.

View in: PubMed
Scully EP, Aga E, Tsibris A, Archin N, Starr K, Ma Q, Morse GD, Squires KE, Howell BJ, Wu G, Hosey L, Sieg SF, Ehui L, Giguel F, Coxen K, Dobrowolski C, Gandhi M, Deeks S, Chomont N, Connick E, Godfrey C, Karn J, Kuritzkes DR, Bosch RJ, Gandhi RT. Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. Clin Infect Dis. 2022 10 12; 75(8):1389-1396.

View in: PubMed
Mina A, Pro B. T time: Emerging and new therapies for peripheral T-cell lymphoma. Blood Rev. 2022 03; 52:100889.

View in: PubMed
Chen J, Zhang J, Shaik NF, Yi B, Wei X, Yang XF, Naik UP, Summer R, Yan G, Xu X, Sun J. The histone deacetylase inhibitor tubacin mitigates endothelial dysfunction by up-regulating the expression of endothelial nitric oxide synthase. J Biol Chem. 2019 12 20; 294(51):19565-19576.

View in: PubMed
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018 09; 19(9):1192-1204.

View in: PubMed
Shustov A, Coiffier B, Horwitz S, Sokol L, Pro B, Wolfson J, Balser B, Eisch R, Popplewell L, Prince HM, Allen SL, Piekarz R, Bates S. Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leuk Lymphoma. 2017 Oct; 58(10):2335-2341.

View in: PubMed
Quagliano A, Gopalakrishnapillai A, Barwe SP. Epigenetic drug combination overcomes osteoblast-induced chemoprotection in pediatric acute lymphoid leukemia. Leuk Res. 2017 05; 56:36-43.

View in: PubMed
Adams CM, Eischen CM. Molecular underpinnings of HDAC inhibition revealed. Cell Cycle. 2016 08 02; 15(15):1943-4.

View in: PubMed
Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, Wolfson J, Coiffier B. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2016 Mar 10; 9:22.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement